How Merck KGaA Uses Light Scattering For Better Developability Assessment Of Biologics

By Bernhard Valldorf, Merck Healthcare KGaA; Adrian Fricke, Philipps-Universität Marburg; and Stefanie Kall, NanoTemper Technologies

The ability to monitor biologic candidates' propensity towards self-association is considered critical for predicting whether a therapeutic is likely to aggregate or become difficult to administer due to viscosity.

Because it is neither practical nor cost-effective to consume large quantities of material early in development, measurements are conducted at low concentrations and used to predict how a formulation will behave at higher, more clinically-relevant concentrations. Precise and reproducible data for these measurements is required for rational decision-making that improves downstream success.

Read how Merck KGaA uses light scattering measurements with Prometheus Panta to prioritize candidates and improve their outcomes.